Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993107 · ClinicalTrials.gov registry record · Phase 3
PALISADE Follow-on Study (ARC004)
A Phase 3 study, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT02993107 is a Phase 3 study that has completed, run by Aimmune Therapeutics. The registered enrollment target is 388 participants.
The verdict
NCT02993107, a Phase 3 study, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
Interventions
- BIOLOGICAL AR101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993107
The ClinicalTrials.gov registry entry for NCT02993107 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR101 is the first listed.
NCT02993107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993107 about?
NCT02993107 is a clinical study titled "PALISADE Follow-on Study (ARC004)". The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
What is the current status of trial NCT02993107?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2016-12-29. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT02993107?
The interventions under investigation include: AR101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02993107?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.